Non-small cell lung cancer Trials in Kuala Lumpur, Malaysia
Conditions / Non-small cell lung cancer / Kuala Lumpur, Malaysia
Non-small cell lung cancer has been the subject of sustained clinical investigation across multiple research sites.
36 total trials for this combination
Showing top 10 of 36 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06120283 | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | RECRUITING | — |
| NCT06765109 | Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC | RECRUITING | PHASE3 |
| NCT06692738 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | RECRUITING | — |
| NCT03447769 | Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A | TERMINATED | PHASE3 |
| NCT05211895 | A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC | RECRUITING | — |
| NCT03425643 | Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT00858364 | Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy | TERMINATED | PHASE3 |
| NCT05120349 | A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection | ACTIVE_NOT_RECRUITING | — |
| NCT03940703 | A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT00949910 | An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | COMPLETED | PHASE4 |